India recorded 6% of global malaria cases in 2016: WHO | WeForNews | Latest News, Blogs India recorded 6% of global malaria cases in 2016: WHO – WeForNews | Latest News, Blogs
Connect with us

Published

on

New Delhi, Nov 29: India recorded six per cent of the world’s new malaria cases in 2016 which stood at 216 million, according to the World Malaria Report 2017 by World Health Organization (WHO).

According to the global health body, 15 countries accounted for 80 per cent of all malaria cases globally in 2016. Nigeria accounted for the highest proportion of cases globally at 27 per cent. Democratic Republic of Congo had 10 per cent, India 6 per cent and Mozambique recorded 4 per cent of the global malaria cases.

India had also witnessed a total of 331 malaria deaths in 2016, making it the highest in the entire Southeast Asia region. The malaria deaths in India were only less to WHO’s Africa region where the figure soared as high as 33,997 for Democratic Republic of Congo.

“Odisha, the highest endemic state of India, reported an increase in cases in 2016 (to double the number in 2013). The other countries had no major outbreaks reported,” according to report.

Between 2014 and 2016, substantial increases in case incidence occurred in the WHO Region of the Americas, and marginally in the WHO Southeast Asia, Western Pacific and African regions.

“In 2016, 85 per cent of estimated vivax malaria cases occurred in just five countries (Afghanistan, Ethiopia, India, Indonesia and Pakistan),” the report said.

In 2016, there were an estimated 445,000 deaths from malaria globally, compared to 446,000 estimated deaths in 2015.

“Plasmodium falciparum is the most prevalent malaria parasite in sub-Saharan Africa, accounting for 99 per cent of estimated malaria cases in 2016. Outside of Africa, P. vivax is the predominant parasite in the WHO Region of the Americas, representing 64 per cent of malaria cases, and is above 30 per cent in the WHO SouthEast Asia and 40 per cent in the Eastern Mediterranean regions,” said the report.

The report also mentions between 2014 and 2016, a total of 582 million insecticide-treated mosquito nets (ITNs) were reported by manufacturers as having been delivered globally.

“Of this amount, 505 million ITNs were delivered in sub-Saharan Africa, compared with 301 million bed nets in the preceding 3-year period (2011-2013),” said the report.

The report states some of the challenges impeding countries’ abilities to stay on track and advance towards elimination include lack of sustainable and predictable international and domestic funding, risks posed by conflict in malaria endemic zones among many others.

It says in 34 of 41 high-burden countries which rely mainly on external funding for malaria programmes, the average level of funding available per person at risk in the past three years (2014-2016) reduced when compared with 2011-2013.

Exceptions were Democratic Republic of Congo, Guinea, Mauritania, Mozambique, Niger, Pakistan and Senegal, which recorded increases.

“Among the 41 high-burden countries, overall, funding per person at risk of malaria remains below $2,” said the report.

The report also pour light on the 76 malaria endemic countries that provided data for 2010 to 2016, resistance to at least one insecticide in one malaria vector from one collection site was detected in 61 countries.

“In 50 countries, resistance to two or more insecticide classes was reported,” said the report.

IANS

Disaster

‘Situation going out of control’: SC seeks Covid report from Delhi, Gujarat, Maharashtra and Assam

A bench headed by Justice Ashok Bhushan said the infections in these states are “going out of control” and asked them to submit a status report within two days.

Published

on

Coronavirus India

The Supreme Court on Monday sought a status report from Delhi, Gujarat, Maharashtra, and Assam on steps taken to control the spread of coronavirus infection, news agency PTI reported. A bench headed by Justice Ashok Bhushan said the infections in these states are “going out of control” and asked them to submit a status report within two days.

“Things have worsened in Delhi especially in November. You file a status report on what steps have been taken,”the court told Additional Solicitor General Sanjay Jain, who was appearing for the Delhi government. The bench, also comprising Justices R S Reddy and M R Shah, said that all efforts shall be made by the Centre and the states to mitigate the situation and to deal with the rising number of COVID-19 cases.

While fresh cases of coronavirus infections continue to decline — or remain stagnant — in the worst-affected states of Maharashtra, Karnataka, and Andhra Pradesh, on the other hand, Haryana, Punjab, Rajasthan, Gujarat, Madhya Pradesh and even Himachal Pradesh have been seeing a significant rise in active cases.

Amid the surge in a few states, the Centre on Sunday dispatched high-level teams to Uttar Pradesh, Punjab and Himachal Pradesh to help them tackle the spread of the disease. A few days ago, similar teams were sent to Rajasthan, Gujarat, Haryana and Chhattisgarh as well.

Part of the reason for the surge in cases in these states could be attributed to low adherence of physical distancing norms during the festival season, especially since it came after a prolonged phase of relative stability, which could have given rise to complacency amongst the public.

On Monday, India’s COVID-19 caseload went past 91 lakh with 44,059 coronavirus infections being reported in a day, while the recoveries surged to 85,62,641. The number of active cases remained below 5 lakh for the thirteenth consecutive day. There are 4,43,486 active cases of coronavirus infection in the country as on date which comprises 4.85 per cent of the total caseload.

Continue Reading

Health

Covid-19: Govt may get Oxford shots in Jan-Feb, at 50% of MRP

The SII has almost completed its phase 3 trials in India and a follow-up of the data is likely to start soon.

Published

on

Vaccine

NEW DELHI: India is likely to get the first lot of anti-Covid shots in late January-early February which will allow some frontline workers like doctors, nurses and municipal staff to get the vaccine. This will be possible as India plans to give Serum Institute of India (SII) emergency use approval for the Oxford-AstraZeneca vaccine candidate soon after it gets similar approval in the UK.

While the SII will need to apply for emergency use, the firm is expected to do so in December. The Centre is finalising a contract with vaccine manufacturers for procurement of doses. The government, which will make bulk purchases, has also negotiated a better price — almost half that of the likely MRP of Rs 500-600 for the two-shot vaccine, an official source said.

Bharat Biotech’s Covaxin can be considered for emergency approval after it submits data from phase I and II trials. Regulatory sources told TOI that Bharat Biotech is in the process of publishing data for the vaccine which is now in phase 3 trials in India. So, two vaccines could be available by February.

“If everything goes as per plan and the company (SII) manages to secure emergency authorisation in December, we are expecting the first lot of vaccines by January-February and the first set of beneficiaries has been identified,” the official said.

While an estimated 50-60 crore doses will be required to inoculate 25-30 crore priority population categorised into four different groups, initially limited stocks are expected by January-end that will be administered mainly to some of the estimated 70 lakh healthcare professionals and over 2 crore frontline workers including police, municipal workers and armed forces.

The SII has almost completed its phase 3 trials in India and a follow-up of the data is likely to start soon.

“If Serum Institute submits its efficacy data from UK and applies for emergency authorisation here, it can easily be granted. But even in case of Bharat Biotech, if the company applies for emergency use approval after its data from phase 1 and 2 are published, the regulator can consider the same,” the official said, indicating that by February-March, more than one vaccine is likely to get at least emergency use authorisation provided the regulator finds data generated from clinical trials satisfactory.

Meanwhile, government is framing terms of references for two major bodies dealing with vaccine introduction — the National Technical Advisory Group on Immunisation and the Central Drug Standards and Control Organisation — to look into grant of emergency authorisation.

Continue Reading

Health

Renowned cardiologist Dr Bansal opens SSB Heart and Multispecialty Hospital in Faridabad

SSB Heart and Multispecialty Hospital which was formally known as ORG Central Hospital near Neelam Flyover, Sector 20A, Faridabad (Delhi-NCR).

Published

on

SSB Heart Dr Bansal

Renowned cardiologist Dr. S.S. Bansal opens SSB Heart and Multispecialty Hospital in Faridabad.

NCR patients requiring heart monitoring and diagnostics can now have a sign of relief as Renowned cardiologist Dr. S.S. Bansal has opened his own hospital.

Dr. Bansal and his entire expert team including Sr. Heart Surgeon, Dr. Sudeep Singh Sidhu has stared the new hospital in the name of SSB Heart and Multispecialty Hospital which was formally known as ORG Central Hospital near Neelam Flyover, Sector 20A, Faridabad (Delhi-NCR).

Dr. Bansal and his whole team including Sr. Heart Surgeon, Dr. Sundeep Sidhu has moved from Metro Hospital Faridabad.

For appointment of Dr. SS Bansal and Dr. Sudeep Singh Sidhu, please contact Mr. Nishant at +91-7669990182.

SSB Heart Dr Bansal Faridabad
Continue Reading
Advertisement

Most Popular

Corona Virus (COVID-19) Live Data

COVID-19 affects different people in different ways. Most infected people will develop mild to moderate illness and recover without hospitalization.